Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Beta-caryophyllene (BCP) is a dietary cannabinoid found in many essential oils, including clove, black pepper, and cannabis. Recent preclinical scientific research has explored its potential neuroprotective effects, including relevance to Alzheimer’s Disease (AD). BCP acts as a selective agonist of the CB2 cannabinoid receptor, which is primarily expressed in immune cells and is associated with anti-inflammatory effects. Neuroinflammation is a key factor in the pathogenesis of AD, and CB2 activation has been shown to help modulate microglial activation and reduce neuroinflammation in animal models.

Several studies in mice have reported that BCP administration can reduce amyloid-beta plaque deposition, improve cognitive performance, and decrease markers of oxidative stress and inflammation in models of AD. For example, a 2014 study published in Phytotherapy Research found that BCP administration improved memory deficits and reduced neuroinflammation in a mouse model of AD. Other studies have similarly demonstrated antioxidant and anti-inflammatory effects, suggesting a protective role in neurodegenerative processes.

However, while these findings are promising, most evidence comes from preclinical models. There is a lack of robust clinical trials in humans, and the efficacy, safety, and optimal dosing of BCP for AD in humans remain unknown. Therefore, while the scientific rationale exists and animal studies are encouraging, the evidence base is still preliminary (rated 2/5). More well-designed human studies are needed before BCP can be recommended for AD treatment.

More about beta caryophyllene
More about Alzheimer's Disease

Other ingredients used for Alzheimer's Disease

Other health conditions supported by beta caryophyllene

Products containing beta caryophyllene